Irregular dosing influences performance of infliximab maintenance therapy in Crohn's
The latest issue of the Inflammatory Bowel Diseases evaluates the impact of prior irregular infliximab dosing on performance of long-term infliximab maintenance therapy in Crohn's disease.
fiogf49gjkf04
Infliximab is efficacious in the management of moderate to severe Crohn's disease.
Our site uses cookies to improve your experience.You can find out more about our use of cookies in our standard cookie policy, including instructions on how to reject and delete cookies if you wish to do so.
By continuing to browse this site you agree to us using cookies as described in our
standard cookie policy .